There is no reliable cure for most types of brain cancer, particularly the most aggressive forms. Some slower-growing brain tumors can be surgically removed and never return, effectively curing the patient. But for glioblastoma, the most common and deadly primary brain tumor in adults, the five-year survival rate remains below 10% even with the best available treatment. That said, the landscape is shifting faster than it has in decades, with immunotherapy, cancer vaccines, and new drug delivery methods entering clinical trials.
Why “Cure” Is Complicated in Brain Cancer
In oncology, a cure means no traces of cancer remain after treatment and the cancer never comes back. Remission is different: it means signs and symptoms have decreased or disappeared, but cancer cells may still be present. Doctors sometimes call a patient “cured” after five or more years of complete remission, though even then, dormant cancer cells can persist in the body.
Brain cancer makes this distinction especially tricky. Glioblastoma tumors are infiltrative, meaning they send microscopic tendrils into surrounding brain tissue that no surgeon can fully remove and no scan can fully detect. Even when imaging looks clean after treatment, recurrence is the norm rather than the exception. Lower-grade brain tumors, by contrast, are more contained and grow more slowly. Some can be completely removed with surgery and may never return, making a true cure possible for a subset of patients.
How Tumor Type Shapes Your Outlook
Not all brain cancers behave the same way, and genetic details within the tumor matter enormously. One of the most important markers is a mutation in a gene called IDH. Patients with grade 3 brain tumors carrying an IDH mutation survive a median of about 81 months, compared to roughly 19 months for patients with the same grade tumor lacking that mutation. That’s a fourfold difference based on a single genetic feature. IDH-mutant tumors tend to respond better to treatment overall and are the focus of newer targeted therapies.
Glioblastoma, which rarely carries IDH mutations, sits at the other end of the spectrum. Standard treatment involves surgery followed by radiation and chemotherapy, and median survival with this approach is 12 to 15 months. Two-year survival rates fall below 30%. These numbers have improved only modestly over the past two decades, which is why so much research energy is now directed at entirely new treatment strategies.
What Standard Treatment Can Do Today
The foundation of brain cancer treatment is still surgery, radiation, and chemotherapy, but refinements in each area are making a measurable difference. Fluorescence-guided surgery uses a compound that makes tumor cells glow under special lighting, helping surgeons distinguish cancer from healthy brain tissue in real time. In high-grade gliomas, this technique more than doubled the rate of complete tumor removal compared to conventional surgery (28% versus 13%). Removing more of the tumor is consistently linked to better outcomes.
Another addition to standard care is a wearable device that delivers low-intensity electrical fields to the scalp, disrupting cancer cell division. When added to the standard combination of radiation and chemotherapy, this approach extended median survival from about 20 months to nearly 25 months in a major clinical trial. Five extra months may sound modest, but in glioblastoma, where progress has been painfully slow, it represented one of the first meaningful survival gains in years.
Getting Drugs Past the Blood-Brain Barrier
One of the central challenges in treating brain cancer is that the brain has its own security system. The blood-brain barrier is a tightly sealed layer of cells lining the brain’s blood vessels, designed to keep toxins and pathogens out. Unfortunately, it also blocks most chemotherapy drugs from reaching tumors at effective doses.
Focused ultrasound is emerging as a way around this problem. The technique uses targeted sound waves, combined with tiny gas-filled bubbles injected into the bloodstream, to temporarily and safely open the barrier in precise locations. This allows drugs to pass into the brain tissue where the tumor sits, then the barrier reseals on its own. The approach is noninvasive, guided by MRI for accuracy, and is being tested in clinical trials as a way to dramatically boost the concentration of cancer-fighting drugs where they’re needed most.
Immunotherapy and Cancer Vaccines
The most exciting developments in brain cancer treatment involve training the immune system to attack tumor cells. Two approaches in particular have generated striking early results.
CAR T-cell therapy takes a patient’s own immune cells, engineers them in a lab to recognize a specific protein on cancer cells, and infuses them back into the body. In a trial involving children with an aggressive and typically fatal type of brain tumor called diffuse midline glioma, 9 of 11 patients saw neurological improvement after receiving CAR T-cells. Seven had measurable tumor shrinkage, and one patient’s tumor disappeared entirely and had not returned after four years. Some children regained the ability to walk, hear, and taste. Participants lived a median of nearly two years after treatment, which is substantially longer than expected for this cancer type. These results are from a small, early trial, but the responses were dramatic enough to accelerate further research.
An experimental mRNA vaccine for glioblastoma takes a different angle. Similar in concept to the mRNA technology used in COVID vaccines, this approach loads fat-coated nanoparticles with genetic instructions taken from a patient’s own tumor. Once injected, immune cells read those instructions, produce proteins that match the tumor, and trigger the immune system to hunt down and destroy any cells carrying those same proteins. The nanoparticles are designed with multiple layers, packing in far more mRNA than standard designs, to provoke a stronger immune response. In an initial trial of four glioblastoma patients, the vaccine produced rapid and strong immune activation in all of them, with measurable spikes in the specific immune cells responsible for killing tumors.
New Drugs for Specific Tumor Types
The STELLAR Phase 3 clinical trial recently tested a drug called eflornithine, which blocks an enzyme involved in tumor cell growth, in combination with an existing oral chemotherapy. The trial enrolled patients with several types of brain tumors. For patients with grade 3 IDH-mutant astrocytoma, the combination helped them live significantly longer. This is notable because Phase 3 positive results for any brain tumor are rare. The drug did not show a benefit for glioblastoma or grade 4 IDH-mutant tumors, reinforcing the idea that different brain cancers require fundamentally different treatment strategies.
Better Detection, Better Monitoring
One of the persistent frustrations in brain cancer care is monitoring whether treatment is working. Standard MRI scans can be ambiguous, sometimes showing changes that look like tumor growth but are actually inflammation from treatment. Liquid biopsy, a technique that analyzes cerebrospinal fluid for fragments of tumor DNA or actual circulating tumor cells, is showing promise as a more precise alternative. In studies so far, detecting circulating tumor cells in spinal fluid has achieved 87% sensitivity and 94% specificity, outperforming traditional methods. Tumor DNA detection was even more sensitive at nearly 98%. These tools aren’t yet standard practice, but they point toward a future where doctors can track brain cancer with greater accuracy and catch recurrence earlier.
What This All Means Right Now
For people with low-grade, surgically accessible brain tumors, a cure is a realistic possibility today. For those with glioblastoma or other high-grade tumors, a cure remains out of reach, but the gap between “terminal diagnosis” and “manageable disease” is narrowing. Immunotherapy results that would have seemed implausible five years ago are now being published. Drug delivery barriers that have stalled progress for decades are being physically opened with ultrasound. Genetic profiling is allowing doctors to match patients with treatments far more precisely than the one-size-fits-all approach of the past. None of this changes the fact that glioblastoma is still among the hardest cancers to treat. But the trajectory of research has shifted from incremental to genuinely new territory.